Cyberknife radiosurgery treatment of peripheral non-small cell lung cancer: Clinical analysis
10.16781/j.0258-879x.2016.01.0098
- Author:
Fang FANG
1
Author Information
1. Department of Radiation Oncology, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Cyberknife;
Lung neoplasms;
Non-small-cell lung carcinoma;
Peripheral lung cancer;
Stereotactic radiotherapy
- From:
Academic Journal of Second Military Medical University
2016;37(1):98-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the short-time outcome and adverse effect of cyberknife in treatment of peripheral non-small cell lung cancer, so as to evaluate the safety and efficacy of cyberknife in treatment of peripheral lung cancer. Methods A total of 66 patients with peripheral non-small cell lung cancer completed their cyberknife radiosurgery, with real-time target tracking through fiducial marker implantation in 25 cases, X-sight lung synchrony in 35 cases, and X-sight spine tracking in 6 cases. Total prescribed dosage ranged from 42 to 60 Gy, with 4 to 6 fractions prescribed to the 65%-75% isodose lines for planning target volume. The biological effective dose (BED) was 71.4-150.0 Gy. The follow-up time was 11-29 months and the median time was 18 months. Results A total of 31 patients had complete radiographic responses, 28 had partial response, 5 patients had stable disease and 2 had progressive disease. The response rate was 89.4%. Tumor size and BED were the significant factors affecting the result of treatment (P=0.019, P=0.007). Conclusion Cyberknife radiosurgery treatment is effective and safe for peripheral non-small cell lung cancer. It can achieve satisfactory tumor control rate, while the long term outcome needs further follow-up.
